

High Concentration Made Simple



WHY CELLENIS® PRP

Cellenis® PRP takes the complexity out of the platelet-rich plasma (PRP) preparation process. It delivers a highly purified platelet concentrate that preserves platelets and removes almost all erythrocytes and neutrophils that promote inflammation.¹



High Concentration

80% (+/- 9%) Platelet Yield + customizable concentrations up to 4.5x*



Monocyte Solution

86.2% of white blood cells in PRP preparation are monocytes



Low Inflammation

Eliminates almost 100% of red blood cells and 95% of granulocytes



Safe & Autologous

Class IIb Medical Device, Regulatory Compliant. Non-Pyrogenic - Sterile -Closed System. FDA Cleared 510(k) Class II Medical Device (BK110035), CE Class IIb



Simple, Quick & Predictable

Small blood draw for high volume plasma, easy to use, reproducible collection process



Comfortable

Proprietary anti-coagulant produces physiologic pH, which reduces irritation²

- 1 Simon M. Chatfi eld, Nathalie Thieblemont, and Véronique Witko-Sarsat. Expanding Neutrophil Horizons: New Concepts in Infl ammation. *J Innate Immun. 2018; PMID: 30257246 PMCID: PMC6785650 DOI: 10.1159/000493101*
- 2 Ehrhardt Proksch. pH in nature, humans and skin. J. Dermatol. 2018 Sep; PMID: 29863755 DOI: 10.1111/1346-8138.14489

FEATURES & BENEFITS



Vacuum sealed, internally coated glass tube designed to:

- Prevent platelets from "sticking" to tube walls
- Precisely draws blood at a pressure that prevents lysing of the cells

Proprietary anti-coagulant modified to:

- Reduce acidity while preventing coagulation of platelets
- Deliver non-activated platelets physically positioned on top of gel


Separator gel designed to:

- Spare up to 80% (+/-9%) of platelets
- Remove 99.9% of RBC
- Remove 95% of granulocytes


^{*} Verified in two published peer reviewed studies. 4.5x achieved by removing PPP prior to collecting PRP.

PRP MADE SIMPLE
















4 FACTS EVERY PRP PROVIDER SHOULD KNOW

- 1. Platelets release growth factors¹
- 2. Cytokines can cause tissue damage²
- 3. Neutrophils inhibit healing³
- 4. Monocytes enhance healing⁴
- 1 Eizaburo Kobayashi, Laura Flückiger, Masako Fujioka-Kobayashi, Kosaku Sawada, Anton Sculean, Benoit Schaller, Richard J Miron. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig. 2016 Dec; PMID: 26809431 DOI: 10.1007/s00784-016-1719-1
- 2 A Ferrante, I C Kowanko, E J Bates. Mechanisms of host tissue damage by cytokineactivated neutrophils. *Immunol Ser.* 1992; PMID: 1504146
- 3 Erminia Mariani, and Lia Pulsatelli. Platelet Concentrates in Musculoskeletal Medicine. Int J Mol Sci. 2020 Feb; DOI: 10.3390/ijms21041328
- 4 José Fábio Lana, Stephany Cares Huber, Joseph Purita, Claudia H. Tambeli, Gabriel Silva Santos, Christian Paulus, and Joyce M. Annichino-Bizzacchi. Leukocyte-rich PRP versus leukocyte-poor PRP The role of monocyte/macrophage function in the healing cascade. *J Clin Orthop Trauma*. 2019 Oct; PMID: 31700202 PMCID: PMC6823808 DOI: 10.1016/j.jcot.2019.05.008





Optimal PRP Formula



Regulatory status: (i) CE certified Class IIb; (ii) FDA cleared 510(k) Class II medical device: Tropocells PRP is intended for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care. The PRP is mixed with autograft or allograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK110035



email us: info@cellenis.com or visit us: www.cellenis.com